Oppenheimer Just Upgraded Intuitive Surgical Stock. Here's Why.

Analysts at Oppenheimer recently upgraded the medtech company Intuitive Surgical (ISRG) from “Perform” to “Outperform” and set a $500 price target, implying a 24.6% upside from current levels. Expecting the company to benefit from the growth in robotic surgery, Oppenheimer analysts expect Intuitive to maintain a leading position in the market despite increasing competition. 

Intuitive also has a vision regarding the usage of artificial intelligence (AI) in such surgeries, helping medical personnel achieve better outcomes. The company is developing AI as a capability stack that leverages real-world surgical data to build advanced vision-language and reasoning models capable of answering complex surgical questions. 

About Intuitive Surgical Stock

Intuitive Surgical is a global medical technology company that designs, manufactures, and markets robotic-assisted surgical systems, instruments, and accessories for minimally invasive procedures. Headquartered in Sunnyvale, California, its core platform is the da Vinci Surgical System, complemented by the Ion endoluminal system for diagnostic lung biopsies. Intuitive has a market capitalization of $141.76 billion. 

Expectations surrounding the stock have cooled while its valuation remains rich. Additional headwinds include concerns that could reduce elective surgery volumes, a lingering product recall of certain da Vinci components, and rising competition. Over the past 52 weeks, Intuitive’s stock has dropped 16.8%, while it is down 29.15% year-to-date (YTD). The stock reached a 52-week low of $328.57 on July 23, but is up 22.13% from that level. 

On a forward-adjusted basis, Intuitive’s price-to-earnings (non-GAAP) ratio of 37.18 times is higher than the industry average of 19.60 times.

Intuitive Surgical Surpassed Q2 Earnings and Revenue Estimates

For the second quarter, Intuitive’s revenue increased 18.5% year-over-year (YOY) to $2.89 billion, which is higher than the $2.82 billion that Wall Street analysts had expected. The majority of the top line came from instrument and accessory sales, which climbed 17.7% YOY to $1.73 billion. 

Moreover, the revenue surge was driven by solid volume expansion. Globally, combined da Vinci and Ion procedures rose about 16% YOY in the second quarter, with da Vinci up roughly 15% and Ion surging around 36%. Intuitive placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. 

The company’s non-GAAP gross profit margin grew from 67.9% to 70%. Non-GAAP net income per share climbed 27.9% YOY to $2.80, surpassing the $2.50 that Street analysts had expected. For the current year, Intuitive expects global da Vinci procedure growth of approximately 13.5% to 15.5%. Its non-GAAP gross profit margin is expected to be between 68% and 69% of revenue. 

Wall Street analysts are optimistic about Intuitive’s future earnings. They expect the company’s EPS to climb by 8.7% YOY to $2.13 for the current quarter. For fiscal 2026, EPS is projected to surge 22.9% annually to $8.87, followed by a 12.7% growth to $10 in fiscal 2027.  

What Analysts are Saying about Intuitive Surgical’s Stock

Before the Oppenheimer upgrade, HSBC analysts downgraded Intuitive’s stock in July from “Buy” to “Hold” and presented a $391 price target. Despite this, sentiment on the stock remains largely positive. 

In the same month, analysts at JPMorgan maintained a bullish “Overweight” rating on Intuitive’s stock, but lowered the price target from $550 to $450. The analyst believes that the company’s in-line procedures and reiterated guidance are overshadowing the robust da Vinci placements and solid profitability. 

Piper Sandler analyst Adam Maeder kept an “Overweight” rating on the stock, while lowering the price target from $580 to $470, noting the company’s better-than-expected Q2 results. Piper Sandler analysts were also pleased to see volume growth and placements exceed consensus estimates.

Wall Street is soundly bullish on Intuitive Surgical’s stock, with analysts awarding it a consensus “Strong Buy” rating overall. Of the 31 analysts rating the stock, 22 have given it a “Strong Buy” rating, two have given it a “Moderate Buy” rating, six have taken the middle-of-the-road approach with a “Hold” rating, and one analyst suggested “Strong Sell.” The consensus price target of $480.93 represents a 19.85% upside from current levels, while the Street-high price target of $685 indicates a 70.7% upside.